Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfredo Addeo

Showing results (201-210 of 224) with videos related to

Pageof 23
Sort By:
Oncology|May 21, 2026
Decision making in intrathecal therapy for leptomeningeal diseaseSusanne Weindler, Thomas Hundsberger, Alfredo Addeo, et al.
Cancer Treatment Reviews|June 1, 2026
PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypesDaniele Marinelli, Fabrizio Citarella, Andrea Torchia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2025
First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLCFederica Pecci, Hui Li, Alessandro Di Federico, et al.
JCO Global Oncology|August 22, 2022
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent ConsiderationsChristian Caglevic, Christian Rolfo, Ignacio Gil-Bazo, et al.
Therapeutic Advances in Medical Oncology|June 28, 2021
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access programOliver Illini, Maximilian Johannes Hochmair, Hannah Fabikan, et al.
JTO Clinical and Research Reports|March 19, 2026
Definitive Radiotherapy With or Without Chemotherapy After Planned Neoadjuvant Chemoimmunotherapy in Stages II to III NSCLC: An International Multicenter Retrospective StudyElio Adib, Amin H Nassar, Katie N Lee, et al.
Thoracic Cancer|December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapyGiuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.
JTO Clinical and Research Reports|May 27, 2022
Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT AnalysisChristine M Bestvina, Jennifer G Whisenant, Valter Torri, et al.
Journal for Immunotherapy of Cancer|February 17, 2022
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinationsAlessio Cortellini, Biagio Ricciuti, Victor R Vaz, et al.
Iscience|October 20, 2023
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysisShobana Anpalakhan, Alessio Signori, Alessio Cortellini, et al.
Pageof 23

Showing results (201-210 of 224) with videos related to

Sort By:
Pageof 23
Oncology|May 21, 2026
Decision making in intrathecal therapy for leptomeningeal diseaseSusanne Weindler, Thomas Hundsberger, Alfredo Addeo, et al.
Cancer Treatment Reviews|June 1, 2026
PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypesDaniele Marinelli, Fabrizio Citarella, Andrea Torchia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2025
First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLCFederica Pecci, Hui Li, Alessandro Di Federico, et al.
JCO Global Oncology|August 22, 2022
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent ConsiderationsChristian Caglevic, Christian Rolfo, Ignacio Gil-Bazo, et al.
Therapeutic Advances in Medical Oncology|June 28, 2021
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access programOliver Illini, Maximilian Johannes Hochmair, Hannah Fabikan, et al.
JTO Clinical and Research Reports|March 19, 2026
Definitive Radiotherapy With or Without Chemotherapy After Planned Neoadjuvant Chemoimmunotherapy in Stages II to III NSCLC: An International Multicenter Retrospective StudyElio Adib, Amin H Nassar, Katie N Lee, et al.
Thoracic Cancer|December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapyGiuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.
JTO Clinical and Research Reports|May 27, 2022
Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT AnalysisChristine M Bestvina, Jennifer G Whisenant, Valter Torri, et al.
Journal for Immunotherapy of Cancer|February 17, 2022
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinationsAlessio Cortellini, Biagio Ricciuti, Victor R Vaz, et al.
Iscience|October 20, 2023
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysisShobana Anpalakhan, Alessio Signori, Alessio Cortellini, et al.
Pageof 23